CR20120448A - Compuesto heterocíclico - Google Patents

Compuesto heterocíclico

Info

Publication number
CR20120448A
CR20120448A CR20120448A CR20120448A CR20120448A CR 20120448 A CR20120448 A CR 20120448A CR 20120448 A CR20120448 A CR 20120448A CR 20120448 A CR20120448 A CR 20120448A CR 20120448 A CR20120448 A CR 20120448A
Authority
CR
Costa Rica
Prior art keywords
heterocyclic compound
compound
cancer
salt
useful
Prior art date
Application number
CR20120448A
Other languages
English (en)
Inventor
Misaki Homma
Toru Miyazaki
Yuya Oguro
Osamu Kurasawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44482985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120448(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR20120448A publication Critical patent/CR20120448A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona un compuesto útil como un agente profiláctico o terapéutico para cáncer. Se describe especificamente un compuesto representado por la fórmula (I) en donde cada símbolo es como se define en la descripción o una sal del mismo, o un promedicamento del compuesto o la sal del mismo, el cual es útil para la prevención o tratamiento de cáncer.
CR20120448A 2010-02-17 2012-08-29 Compuesto heterocíclico CR20120448A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010031899 2010-02-17
JP2010131950 2010-06-09

Publications (1)

Publication Number Publication Date
CR20120448A true CR20120448A (es) 2012-11-13

Family

ID=44482985

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120448A CR20120448A (es) 2010-02-17 2012-08-29 Compuesto heterocíclico

Country Status (37)

Country Link
US (6) US8722660B2 (es)
EP (2) EP2540728B1 (es)
JP (1) JP5689454B2 (es)
KR (1) KR101735868B1 (es)
CN (1) CN102844320B (es)
AU (1) AU2011216404B2 (es)
BR (1) BR112012020311B1 (es)
CA (1) CA2790284C (es)
CL (1) CL2012002250A1 (es)
CO (1) CO6592104A2 (es)
CR (1) CR20120448A (es)
CY (1) CY1121792T1 (es)
DK (1) DK2540728T3 (es)
DO (1) DOP2012000224A (es)
EA (1) EA020724B1 (es)
EC (1) ECSP12012160A (es)
ES (1) ES2733221T3 (es)
GE (1) GEP20146202B (es)
HR (1) HRP20190947T1 (es)
HU (1) HUE043514T2 (es)
IL (1) IL221442A0 (es)
LT (1) LT2540728T (es)
MA (1) MA34064B1 (es)
ME (1) ME03410B (es)
MX (1) MX353500B (es)
MY (1) MY164776A (es)
NZ (1) NZ602089A (es)
PE (1) PE20130184A1 (es)
PH (1) PH12012501650B1 (es)
PL (1) PL2540728T3 (es)
PT (1) PT2540728T (es)
RS (1) RS58796B1 (es)
SG (1) SG183304A1 (es)
SI (1) SI2540728T1 (es)
SM (1) SMT201900385T1 (es)
TN (1) TN2012000401A1 (es)
WO (1) WO2011102399A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013001660A (es) * 2010-08-11 2013-06-03 Millenium Pharmaceuticals Inc Heteroarilos y usos de los mismos.
JP6569908B2 (ja) 2014-01-31 2019-09-04 カルナバイオサイエンス株式会社 抗がん剤組成物
TW201620879A (zh) 2014-04-28 2016-06-16 杜邦股份有限公司 除草性經取代之３－苯基－４－氟基苯甲醯基吡唑
US10174032B2 (en) * 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
JP6605042B2 (ja) 2015-12-07 2019-11-13 ザイマージェン インコーポレイテッド Ｈｔｐゲノム操作プラットフォームによる微生物株の改良
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
US11746109B2 (en) * 2016-03-28 2023-09-05 Takeda Pharmaceutical Company Limited Crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate
EA035560B1 (ru) * 2016-07-28 2020-07-07 Такеда Фармасьютикал Компани Лимитед Кристаллические формы гемигидрата 2-[(2s)-1-азабицикло[2.2.2]окт-2-ил]-6-(3-метил-1h-пиразол-4-ил)тиено[3,2- d]пиримидин-4(3h)-она
CN110088100B (zh) 2016-11-08 2023-02-17 癌症研究科技有限公司 作为cdc7抑制剂的嘧啶酮衍生物
EP3589747B1 (en) 2017-03-01 2021-05-19 Takeda Pharmaceutical Company Limited Method of predicting effects of cdc7 inhibitor
US10745410B2 (en) 2017-05-21 2020-08-18 Zenji Research Laboratories Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
JP7416713B2 (ja) * 2018-04-02 2024-01-17 武田薬品工業株式会社 ２－［（２Ｓ）－１－アザビシクロ［２．２．２］オクト－２－イル］－６－（３－メチル－１Ｈ－ピラゾール－４－イル）チエノ［３，２－ｄ］ピリミジン－４（３Ｈ）－オンの合成のためのプロセス
TWI846703B (zh) 2018-06-19 2024-07-01 日商武田藥品工業股份有限公司 癌症治療方法
KR20210033483A (ko) * 2018-07-19 2021-03-26 다케다 야쿠힌 고교 가부시키가이샤 Cdc7 억제제를 갖는 약제학적 조성물
EP3856352A4 (en) 2018-09-24 2022-06-29 Sierra Oncology, Inc. Methods of treatment of cancer comprising cdc7 inhibitors
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
US20220235068A1 (en) * 2019-05-30 2022-07-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tetracyclic compounds as cdc7 inhibitors
BR112022000734A2 (pt) 2019-07-19 2022-04-12 Takeda Pharmaceuticals Co Método para tratar câncer em um paciente, uso de composto 1, e, composto 1
US20220389026A1 (en) * 2019-08-20 2022-12-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tetracyclic compound used as cdc7 inhibitor
EP4069369A4 (en) * 2019-12-06 2024-02-14 Schrödinger, Inc. CYCLIC COMPOUNDS AND METHODS OF USE
JP2023541047A (ja) * 2020-09-10 2023-09-27 シュレーディンガー， インコーポレイテッド がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤
JP2023551134A (ja) * 2020-11-30 2023-12-07 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｃｄｃ７阻害剤としての塩及びその結晶形
CN112661770B (zh) * 2020-12-24 2022-11-08 南京正济医药研究有限公司 一种化合物及利用其制备取代的[5,6]环-4(3h)-嘧啶酮化合物的方法
WO2022167999A1 (en) 2021-02-08 2022-08-11 Takeda Pharmaceutical Company Limited Combination therapy for cancer treatment
CN117120447A (zh) * 2021-03-18 2023-11-24 薛定谔公司 环状化合物和其使用方法
TW202300150A (zh) * 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
TW202330552A (zh) * 2021-10-13 2023-08-01 美商雷密克斯醫療公司 調節剪接之化合物及方法
WO2025160538A1 (en) * 2024-01-26 2025-07-31 The Board Of Regents Of The University Of Texas System Compositions and methods for treating hair graying and loss associated with aging
WO2025168620A1 (en) 2024-02-07 2025-08-14 Bayer Aktiengesellschaft Heteroaryl-substituted 4,5-dihydro-1h-2,4,5-oxadiazines as novel fungicides

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA782648B (en) * 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
KR20030034232A (ko) 2000-09-29 2003-05-01 닛뽕소다 가부시키가이샤 티에노피리미딘 화합물 및 그 염 및 제조방법
US6503914B1 (en) 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
US20030096813A1 (en) 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
ATE323702T1 (de) 2002-08-06 2006-05-15 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
DE602004022819D1 (de) 2003-06-06 2009-10-08 Vertex Pharma Von atp-bindende kassette transportern
PL1641803T6 (pl) * 2003-06-11 2011-04-29 Xention Ltd Pochodne tienopirymidyny jako inhibitory kanału potasowego
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
BRPI0413438A (pt) * 2003-08-08 2006-10-17 Pharmacia Italia Spa derivados de pirimidilpirrol ativos como inibidores de cinase
US7279575B2 (en) 2003-08-08 2007-10-09 Pfizer Italia S.R.L. Pyrimidylpyrrole derivatives active as kinase inhibitors
MXPA06010520A (es) 2004-03-30 2007-03-26 Chiron Corp Derivados de tiofeno sustituidos como agentes anticancerosos.
EP2520652B1 (en) 2004-04-09 2015-06-10 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
EP1856128A4 (en) 2005-01-19 2009-12-23 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
JP2009501217A (ja) 2005-07-15 2009-01-15 アストラゼネカ アクチボラグ 治療薬
KR101149954B1 (ko) 2005-08-30 2012-06-01 아사히 가세이 파마 가부시키가이샤 술폰아미드 화합물
FI20055498A0 (fi) 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US20070142414A1 (en) 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
KR100846988B1 (ko) 2006-03-06 2008-07-16 제일약품주식회사 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
US20090030196A1 (en) 2006-12-29 2009-01-29 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20090118276A1 (en) 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
WO2009112490A1 (en) 2008-03-11 2009-09-17 Cellzome Limited Sulfonamides as zap-70 inhibitors
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
RU2011102743A (ru) 2008-06-26 2012-08-10 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения
EP2403857B1 (en) 2009-03-05 2013-12-04 Takeda Pharmaceutical Company Limited Thienopyrimidine as cdc7 kinase inhibitors
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
CN102481294A (zh) 2009-09-11 2012-05-30 拜耳医药股份有限公司 作为抗癌药物的取代(杂芳基甲基)乙内酰硫脲
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
AR079343A1 (es) 2009-12-21 2012-01-18 Lilly Co Eli Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico

Also Published As

Publication number Publication date
NZ602089A (en) 2014-05-30
EP2540728B1 (en) 2019-04-10
US20140235615A1 (en) 2014-08-21
HUE043514T2 (hu) 2019-08-28
DK2540728T3 (da) 2019-05-13
KR20130001246A (ko) 2013-01-03
US9655900B2 (en) 2017-05-23
MX353500B (es) 2018-01-16
MA34064B1 (fr) 2013-03-05
PE20130184A1 (es) 2013-03-09
EP3533797B1 (en) 2023-12-20
SI2540728T1 (sl) 2019-06-28
SG183304A1 (en) 2012-09-27
MY164776A (en) 2018-01-30
BR112012020311A2 (pt) 2017-03-01
RS58796B1 (sr) 2019-07-31
EA201290800A1 (ru) 2013-03-29
PH12012501650A1 (en) 2012-10-22
HRP20190947T1 (hr) 2019-07-26
CN102844320A (zh) 2012-12-26
PL2540728T3 (pl) 2019-09-30
LT2540728T (lt) 2019-06-25
BR112012020311B1 (pt) 2019-01-29
EP2540728A1 (en) 2013-01-02
US20150158882A1 (en) 2015-06-11
EA020724B1 (ru) 2015-01-30
CN102844320B (zh) 2016-03-23
AU2011216404A1 (en) 2012-09-20
US20130029969A1 (en) 2013-01-31
PT2540728T (pt) 2019-07-11
MX2012009602A (es) 2012-12-17
US9388195B2 (en) 2016-07-12
US8933069B2 (en) 2015-01-13
JPWO2011102399A1 (ja) 2013-06-17
CA2790284C (en) 2019-01-08
AU2011216404B2 (en) 2016-04-07
CA2790284A1 (en) 2011-08-25
CO6592104A2 (es) 2013-01-02
US20170209452A1 (en) 2017-07-27
SMT201900385T1 (it) 2019-09-09
JP5689454B2 (ja) 2015-03-25
US20140228352A1 (en) 2014-08-14
US8722660B2 (en) 2014-05-13
CL2012002250A1 (es) 2013-02-08
US20160310494A1 (en) 2016-10-27
US8921354B2 (en) 2014-12-30
ME03410B (me) 2020-01-20
GEP20146202B (en) 2014-11-25
KR101735868B1 (ko) 2017-05-15
TN2012000401A1 (en) 2014-01-30
DOP2012000224A (es) 2013-01-31
WO2011102399A1 (ja) 2011-08-25
PH12012501650B1 (en) 2018-11-07
ECSP12012160A (es) 2013-03-28
IL221442A0 (en) 2012-10-31
EP3533797A1 (en) 2019-09-04
ES2733221T3 (es) 2019-11-28
EP2540728A4 (en) 2013-11-06
CY1121792T1 (el) 2020-07-31

Similar Documents

Publication Publication Date Title
CR20120448A (es) Compuesto heterocíclico
MX2013006113A (es) Compuestos biciclico.
EA201400178A1 (ru) Лечение рака молочной железы
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
MX373786B (es) Derivados de pirimidin-2,4-diamina para el tratamiento de cáncer.
SI3725810T1 (sl) Kombinacijska terapija, ki vključuje protitelesa proti klavdinu 18.2 za zdravljenje raka
ECSP14013329A (es) Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX368392B (es) Compuesto heterociclico fusionado.
ECSP10010526A (es) Compuesto heterociclico
CR20140537A (es) Compuesto heterocíclico nitrogenado
MX361499B (es) Baricitinib deuterado.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EA201591024A1 (ru) Димерные соединения
PH12015500399A1 (en) Azaindolines
EA201491581A1 (ru) Везикулярные композиции
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку
EA201691036A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии
MX2015012043A (es) Agonistas muscarinicos.
UY35165A (es) Método profiláctico o terapéutico para el síndrome de sjogren
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
NZ717880A (en) Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors
MX2015012610A (es) Pacritinib deuterizado.